Lifearc invests £1.3 billion into identification, treatment, and prevention of disease

Laboratory

British life science medical research charity, Lifearc, aims to invest £1.3 billion into diagnostics, drugs, and technology that will revolutionize identification, treatment and prevention of diseases such as MND (motor neurone disease).

The company will work alongside associates to provide medical results that can change the lives of patients.

“The company will work alongside associates to provide medical results that can change the lives of patients“

When it comes to taking research from laboratories and transferring them to patients, Lifearc has over 25 years under their belt. They will carry out their strategy by collaborating with partners including charities, patient groups and academic researchers.

Translation expertise will allow patients, the research & development and clinical communities to collaborate and resolve issues that are considered imperative to patients.

A portion of Lifearc’s spending will be through venture capital, this will subsidize business’ that are in initial stages of development up to the size necessary to appeal to investors and raise subsequent financing.

Chief Executive Officer at Lifearc, Dr Melanie Lee, said that "Our commitment to invest and our new strategy shows we are now ambitious on an entirely new scale. We want to invest significant resources so that patient-focused life science innovations in the UK can truly flourish. Scientific understanding is constantly evolving and the latest advances in technology have the power to revolutionise healthcare.”

She continued: “Scientists have the imagination, determination, and knowledge to transform healthcare but translating science is a long, expensive, and risky process. Spotting opportunities and knowing what to do with them requires specialised knowledge. Too few ideas ever make it out of the lab. That’s where LifeArc comes in – to move more ideas down the research pipeline towards the clinic. I am really excited about our new strategy and the difference we, together with our partners, will make for patients."

Return to news